Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Ventricular assist devices

Other efforts have led to the development of ventricular assist devices to support the heart for several months and intra-aortic balloon pumps (lABPs) which are widely used to unload and stabilize the heart. [Pg.181]

The ventricular assist device (VAD) is a surgically implanted pump that reduces or replaces the work of the right, left, or both ventricles. Ventricular assist devices are currently indicated for short-term support in patients refractory to pharmacologic therapies, as long-term bridge therapy (a temporary transition treatment) in patients awaiting cardiac transplant, or in some instances, as the destination therapy (treatment for patients in lieu of cardiac transplant for those who are not appropriate candidates for transplantation).1 The most common complications are infection and thromboembolism. Other... [Pg.59]

Cardiac transplantation is one option for patients with severe heart failure. Candidates for cardiac transplantation generally present with New York Heart Association (NYHA) class III or IV symptoms and have an ejection fraction of less than 25%.1,3 The general indications for cardiac transplantation include rapidly declining cardiac function and a projected 1-year mortality rate of greater than 75%. Mechanical support with an implantable left ventricular assist device may be appropriate while patients await the availability of a viable organ.1,3 Some additional reasons for heart transplant include ... [Pg.830]

Snyder TA, Tsukui H, Kihara S et al (2007) Preclinical biocompatibility assessment of the EVAHEART ventricular assist device coating comparison and platelet activation. J Biomed Mater Res A 81 85-92... [Pg.166]

SECTION 2 Cardiovascular Disorders Ventricular Assist Devices... [Pg.109]

Ventricular assist devices are surgically implanted and assist, or in some cases replace, the pumping functions of the right and/or left ventricles. [Pg.109]

Ventricular assist devices can be used in the short-term (days to several weeks) for temporary stabilization of patients awaiting an intervention to correct the underlying cardiac dysfunction. They can also be used long term (several months to years) as a bridge to heart transplantation. Permanent device implantation has recently become an option for patients who are not candidates for heart transplantation. [Pg.109]

Wohlschlaeger J, Schmitz KJ, Schmid C, Schmid KW, Keul P, Takeda A, et al. Reverse remodeling following insertion of left ventricular assist devices (LVAD) a review of the morphological and molecular changes. Cardiovasc Res 2005 68 376-386. [Pg.90]

Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998 98 656-662... [Pg.90]

Barbone A, Holmes JW, Heerdt PM, The AH, Naka Y, Joshi N, Daines M, Marks AR, Oz MC, Burkhoff D. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure a primary role of mechanical unloading underlying reverse remodeling. Circulation 2001 104 670-675... [Pg.90]

Hetzer R, Muller JH, Weng YG, Loebe M, Wallukat G. Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy. J Thorac Cardiovasc Surg 2000 120 843-853... [Pg.90]

Yacoub MH. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery. Eur Heart J 2001 22 534-540... [Pg.90]

Burkhoff D, Cohen H, Brunckhorst C, O Neill WW. A randomized multicenter chnical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006 152 469el-469e8... [Pg.92]

Vranckx P, Foley DP, Feijter PJ, Vos J, Smits P, Serruys PW. Clinical introduction of the Tandem-heart, a percutaneous left ventricular assist device, for circulatory support during high-risk percutaneous coronary intervention. Internat J Cardiovasc Intervent 2003 5 35-39... [Pg.92]

Radovancevic B, Vrtovec B, Frazier OH. Left ventricular assist devices an alternative to medical therapy for end-stage heart failure. Cwr Opin Cardiol 2003 18 210-214. [Pg.121]

Current long-term mechanical support devices such as left ventricular assist devices (LVADs) require use of the heart lung machine and extensive surgery. The... [Pg.134]

Vatta M, Stetson SJ, Jimenez S, et al. Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. J Am Coll Cardiol. Mar3 2004 43(5) 811-817. [Pg.140]

In recipients of left ventricular assist devices awaiting cardiac transplantation treated with intravenous immunoglobulin, clinical manifestations of immune complex... [Pg.1724]

John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, Edwards N, Rose E, Oz M, Itescu S. Intravenous immunoglobuhn reduces anti-HLA allo-reactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999 100(Suppl 19) II229-35. [Pg.1729]

Devices principally contacting blood (pacemaker electrodes, heart valves, vascular grafts and stents, internal drug delivery catheters, and ventricular assist devices)... [Pg.284]

C. M. Ballantyne, M. S. Verani, H. D. Short, C. Hyatt, G. P. Noon, Delayed recovery of severely stunned myocardium with the support of a left ventricular assist device after coronary artery bypass graft surgery, J Am Coll Cardiol 10, 710-712 (1987). [Pg.190]

PAOP pulmonary artery occlusion pressure P-gp P-glycoprotein RAA renin-angiotensin-aldosterone RVF right ventricular failure SDC serum digoxin concentration S VR systemic vascular resistance TNF-a tumor necrosis factor-a TZD thiazolidinedione VAD ventricular assist device... [Pg.257]

Despite all these efforts, patients continue to die awaiting transplant. In 2001, over 6000 people died on transplant waiting lists. While renal dialysis may be used for an extended period of time to partially replace the function of the kidneys, such options are not readily available for all liver and heart transplant candidates. Hepato-cyte transplantation and artiflcal liver support are areas of research as alternatives or bridges to liver transplantation. Left-ventricular assist devices (LVADs) are now used commonly as a bridge to transplantation for many heart transplant candidates. [Pg.1613]

Absolute contraindications to orthotopic cardiac transplantation include the presence of an active infection (except in the case of an infected ventricular assist device, which is an indication for urgent transplantation) or the presence of other diseases (i.e., mahgnancy) that may limit survival and/or rehabihtation and severe, irreversible pulmonary hypertension. [Pg.1614]

See other pages where Ventricular assist devices is mentioned: [Pg.183]    [Pg.183]    [Pg.205]    [Pg.59]    [Pg.61]    [Pg.535]    [Pg.131]    [Pg.205]    [Pg.325]    [Pg.254]    [Pg.254]    [Pg.254]    [Pg.1635]    [Pg.1640]    [Pg.147]   
See also in sourсe #XX -- [ Pg.59 ]

See also in sourсe #XX -- [ Pg.428 ]

See also in sourсe #XX -- [ Pg.88 ]

See also in sourсe #XX -- [ Pg.129 ]

See also in sourсe #XX -- [ Pg.127 , Pg.134 , Pg.137 ]



SEARCH



Left ventricular assist device

Left ventricular assist devices LVADs)

Left ventricular assist devices infections

Polyurethanes ventricular assist devices

Ventricular

© 2024 chempedia.info